Preferred Label : Farletuzumab Ecteribulin;
NCIt synonyms : Anti-FRA/Eribulin ADC MORAb-202; Anti-FRA ADC MORAb-202; Anti-FRA/Eribulin Antibody-drug Conjugate MORAb-202; ADC MORAb-202;
NCIt definition : An antibody drug conjugate (ADC) composed of farletuzumab, a humanized immunoglobulin
G1 (IgG1) monoclonal antibody directed against the folate receptor alpha (FRA; FolRa;
FOLR1), and conjugated, via a cathepsin B-cleavable linker, to the microtubule-targeting
agent (MTA) eribulin, a derivative of the macrocyclic polyether natural product halichondrin
B, with potential antineoplastic activity. Upon administration of farletuzumab ecteribulin,
the farletuzumab moiety targets and binds to FRA expressed on certain tumor cells.
Upon binding, internalization, and enzymatic cleavage, eribulin binds to the vinca
domain of tubulin and inhibits the polymerization of tubulin and the assembly of microtubules,
resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest
at G2/M phase, and the induction of tumor cell death in FRA-expressing cells. FRA
is a glycosylphosphatidylinositol linked cell-surface glycoprotein that is widely
expressed in certain cancers while its expression is limited in normal tissues.;
UNII : UVG3B5TZN3;
CAS number : 2407465-18-1; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2407465-18-1
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : MORAb-202; MORAb 202;
NCI Metathesaurus CUI : CL1407865;
Origin ID : C173946;
UMLS CUI : C5667208;
Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_target
